{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:54:46Z","timestamp":1776779686945,"version":"3.51.2"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1097\/mnm.0b013e32835aaa48","type":"journal-article","created":{"date-parts":[[2012,10,30]],"date-time":"2012-10-30T08:47:34Z","timestamp":1351586854000},"page":"50-56","source":"Crossref","is-referenced-by-count":13,"title":["The incidence of secondary central nervous system involvement in patients with non-Hodgkin\u2019s lymphoma as detected by 18F-FDG PET\/CT"],"prefix":"10.1097","volume":"34","author":[{"given":"Burcu E.","family":"Akkas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulin U.","family":"Vural","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210212","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/annonc\/mdp432","article-title":"Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.","volume":"21","author":"Villa","year":"2010","journal-title":"Ann Oncol"},{"key":"R2-9-20210212","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.hoc.2005.05.003","article-title":"Diagnosis and treatment of central nervous system involvement in non-Hodgkins lymphoma.","volume":"19","author":"Bierman","year":"2005","journal-title":"Hematol Oncol Clin North Am"},{"key":"R3-9-20210212","first-page":"Doc11","article-title":"Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis.","volume":"9","author":"Patrij","year":"2011","journal-title":"Ger Med Sci"},{"key":"R4-9-20210212","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1210\/jc.2003-030395","article-title":"Tumors metastatic to the pituitary gland: case report and literature review.","volume":"89","author":"Komninos","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"R5-9-20210212","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/10428190802311458","article-title":"Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment.","volume":"49","author":"Van Besien","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 2","key":"R7-9-20210212","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminoncol.2009.05.002","article-title":"Central nervous system disease in hematologic malignancies: historical perspective and practical applications.","volume":"36","author":"Pui","year":"2009","journal-title":"Semin Oncol"},{"key":"R8-9-20210212","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1182\/blood-2007-07-101402","article-title":"Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report.","volume":"111","author":"Doolittle","year":"2008","journal-title":"Blood"},{"key":"R9-9-20210212","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/annonc\/mdh013","article-title":"Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab.","volume":"15","author":"Feugier","year":"2004","journal-title":"Ann Oncol"},{"key":"R10-9-20210212","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood-2008-10-182253","article-title":"CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).","volume":"113","author":"Boehme","year":"2009","journal-title":"Blood"},{"key":"R12-9-20210212","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3174\/ajnr.A2171","article-title":"Central nervous system lymphoma: characteristic findings on traditional and advanced imaging.","volume":"32","author":"Haldorsen","year":"2011","journal-title":"Am J Neuroradiol"},{"key":"R14-9-20210212","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11102-005-4535-1","article-title":"Lymphoma metastasizing to the pituitary: an unusual presentation of a treatable disease.","volume":"8","author":"Megan Ogilvie","year":"2005","journal-title":"Pituitary"},{"key":"R15-9-20210212","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s12185-012-1075-0","article-title":"Pituitary lymphoma developing within pituitary adenoma.","volume":"95","author":"Morita","year":"2012","journal-title":"Int J Hematol"},{"key":"R16-9-20210212","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.blre.2006.02.001","article-title":"CNS prophylaxis in lymphoma: who to target and what therapy to use.","volume":"20","author":"Hill","year":"2006","journal-title":"Blood Rev"},{"key":"R17-9-20210212","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11060-009-9898-0","article-title":"CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission.","volume":"95","author":"Stefoni","year":"2009","journal-title":"J Neurooncol"},{"key":"R18-9-20210212","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3816\/CLM.2001.n.017","article-title":"High-dose methotrexate for isolated central nervous system relapse in patients with testicular non-Hodgkins lymphoma.","volume":"2","author":"Batchelor","year":"2001","journal-title":"Clin Lymphoma"},{"key":"R19-9-20210212","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbmt.2011.07.006","article-title":"Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.","volume":"18","author":"Cote","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"R20-9-20210212","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1002\/cncr.25278","article-title":"Intravenous methotrexate as central nervous system prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.","volume":"116","author":"Abramson","year":"2010","journal-title":"Cancer"},{"key":"R21-9-20210212","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/annonc\/mdl327","article-title":"Incidence and risk factors of central nervous system recurrence in aggressive lymphoma - a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL).","volume":"18","author":"Boehme","year":"2007","journal-title":"Ann Oncol"},{"key":"R22-9-20210212","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2141.2005.05703.x","article-title":"Central nervous system-directed preventative therapy in adults with lymphoma.","volume":"131","author":"McMillan","year":"2005","journal-title":"Br J Haematol"},{"key":"R23-9-20210212","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1080\/1042819021000006475","article-title":"Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate grade non-Hodgkins lymphoma.","volume":"43","author":"Chua","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"R24-9-20210212","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/RLU.0b013e31821739e3","article-title":"Use of F-18 FDG PETCT in non-Hodgkin lymphoma with central nervous system involvement.","volume":"36","author":"Cimarelli","year":"2011","journal-title":"Clin Nucl Med"},{"key":"R25-9-20210212","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.rcl.2007.05.009","article-title":"Fluorine-18 fluorodeoxyglucose PETCT patterns of extranodal involvement in patients with non-Hodgkin lymphoma and Hodgkins disease.","volume":"45","author":"Even-Sapir","year":"2007","journal-title":"Radiol Clin North Am"},{"key":"R26-9-20210212","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1002\/cncr.22276","article-title":"FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.","volume":"107","author":"Kostakoglu","year":"2006","journal-title":"Cancer"},{"key":"R27-9-20210212","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/annonc\/mdi272","article-title":"The deleted FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.","volume":"16","author":"Mikhaeel","year":"2005","journal-title":"Ann Oncol"},{"key":"R28-9-20210212","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma.","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"R29-9-20210212","first-page":"532","article-title":"Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography.","volume":"33","author":"Rosenfeld","year":"1992","journal-title":"J Nucl Med"},{"key":"R30-9-20210212","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11060-010-0182-0","article-title":"Prognostic value of pretreatment 18F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment.","volume":"100","author":"Kawai","year":"2010","journal-title":"J Neurooncol"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00006231-201301000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:49:45Z","timestamp":1618037385000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006231-201301000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0b013e32835aaa48","relation":{},"ISSN":["0143-3636"],"issn-type":[{"value":"0143-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}